Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(CSE: MBIO )

0.0550 UNCHANGED
Streaming Delayed Price Updated: 9:42 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,000
Open 0.0550
Bid (Size) 0.0550 (48,000)
Ask (Size) 0.0650 (20,000)
Prev. Close 0.0550
Today's Range 0.0550 - 0.0550
52wk Range 0.0150 - 0.5600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LSD Microdosing For PMS? After Confirming Antidepressant Effects, Clinical Trials Will Assess If It Addresses Mood Issues
Via Benzinga
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
Via ACCESSWIRE

Performance

YTD
+175.00%
+175.00%
1 Month
+10.00%
+10.00%
3 Month
+175.00%
+175.00%
6 Month
+83.33%
+83.33%
1 Year
-81.97%
-81.97%

More News

Read More
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
Via ACCESSWIRE
Lender Requests to Convert Loan to MindBio Shares
Via ACCESSWIRE
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Via ACCESSWIRE
MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Via ACCESSWIRE
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
Via ACCESSWIRE
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
Via ACCESSWIRE
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
Via ACCESSWIRE
MindBio Therapeutics CEO Provides End of Year Video Update on Phase 2 Clinical Trials
Via ACCESSWIRE
MindBio Therapeutics Team Members Honoured with Industry Leading Awards
Via ACCESSWIRE
MindBio Therapeutics CEO Presents World First Phase 2B Take-Home Microdosing Clinical Trial in Cancer Patients
Via ACCESSWIRE
MindBio Therapeutics Begins Dosing MB22001 in World First Phase 2B Microdosing Clinical Trial In Advanced Stage Cancer Patients
Via ACCESSWIRE
Mindbio Therapeutics Nominated for Company of the Year in Industry Awards
Via ACCESSWIRE
MindBio Therapeutics CEO Provides Video Update on Phase 2a Depression Trial Using MB22001
Via ACCESSWIRE
Tenth Patient With Depression Starts Dosing MB22001 in Take Home Microdosing Trials
Via ACCESSWIRE
Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research
Via ACCESSWIRE
MindBio Therapeutics Announces Major Genetic Discovery in Microdosing Research
Via ACCESSWIRE
Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression
Via ACCESSWIRE
Mindbio Therapeutics First Batch of MB22001 has Been Manufactured and is Ready for Use in World First Phase 2 Take at Home Psychedelic Clinical Trials
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.